Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Jul 3, 2024
Product Development
Clinical Report: Updates in myasthenia gravis from J&J, Cartesian
Plus: Readouts for Savara, Lyell and Novo Nordisk
BioCentury | Nov 17, 2023
Product Development
AstraZeneca looks to new CKD combinations to extend Farxiga’s reign
AZ is moving Farxiga combinations into Phase III testing that it believes can help reach underserved patient subsets
BioCentury | Aug 29, 2022
Regulation
Aug. 29 Quick Takes: Novartis’ Scemblix wins EU approval in leukemia setting
Plus Farxiga demonstrates survival benefit and a Teva-MedinCell antipsychotic enters Phase III
BioCentury | Jun 4, 2022
Emerging Company Profile
Heqet: regenerating heart muscle cells via the Hippo pathway
King’s College spinout is inducing cardiomyocyte regeneration via nanoparticle-delivered miRNA
BioCentury | Jul 10, 2021
Deals
July 9 Quick Takes: Novo-built Muna launches with $73M series A; plus Sigilon, bluebird, Vectura, BeiGene, Bayer and more
Launching with a $73 million series A round, small molecule neurodegeneration play Muna Therapeutics is based on technology from the labs of two professors: Simon Glerup from Denmark's Aarhus
BioCentury | Jan 15, 2021
Regulation
Jan. 14 Quick Takes: Lexicon rises on NDA timeline for heart failure program; plus: FDA COVID reports and updates from BeiGene, Merck, Bayer
Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) gained $4.13 (105%) to $8.05 Thursday after saying data from its Phase III SOLOIST and SCORED trials of sotagliflozin could support an NDA submission as
BioCentury | Oct 16, 2020
Product Development
Recent Phase III disappointment aside, the heart failure pipeline holds plenty to look forward to
Drug development for heart failure is picking up, with five clinical readouts from five mechansims expected in the next year
BioCentury | Jul 19, 2019
Regulation
A half step forward for heart failure as FDA guidance leaves key question unanswered
FDA will need to nail down details in its heart failure guidance to really boost investment
Items per page:
1 - 10 of 38